The proteomic response of Clostridioides difficile to the Chlorotonil A derivative ChtB1-Epo2

The anaerobic, spore-forming pathogen Clostridioides difficile infects the gastrointestinal tract of higher mammals, including humans, and is the major causative agent of antibiotic-associated diarrhea. Moreover, recurrence and re-infection rates after a first successful antibiotic therapy are substantially high. To overcome the problem of recurrence and re-infection new antibiotics are urgently required that are more selective for the pathogen but spare other members of the microbiota. In turn, the microbial community inside the intestine is allowed to recover and to re-establish colonization resistance to protect against recurrence. The data presented here aim at analyzing the ability of the macrolide compound chlorotonil A to meet the requirements of C. difficile specific drug.

艰难梭菌（Clostridioides difficile）是一种厌氧产芽孢病原菌，可感染包括人类在内的高等哺乳动物的胃肠道，亦是抗生素相关性腹泻的主要致病菌。此外，经首次成功的抗生素治疗后，疾病复发与再感染率仍处于较高水平。为解决复发与再感染难题，亟需开发对该病原菌具有更高选择性、且不会损害肠道微生物组中其他菌群成员的新型抗生素，以使肠道微生物群落得以恢复并重新建立定植抗性，从而抵御疾病复发。本数据集所呈现的实验数据，旨在评估大环内酯类化合物氯托尼尔A（chlorotonil A）是否满足艰难梭菌特异性治疗药物的研发要求。